Hypercalcemia Workup Algorithm
The initial workup of hypercalcemia begins with measuring serum intact parathyroid hormone (PTH), which distinguishes PTH-dependent from PTH-independent causes and directs all subsequent diagnostic and therapeutic decisions 1.
Step 1: Confirm Hypercalcemia and Assess Severity
- Verify elevated calcium: Measure ionized calcium or correct total calcium for albumin
- Classify severity 2:
- Mild: Total calcium <12 mg/dL (<3 mmol/L)
- Moderate: Total calcium 12-14 mg/dL (3-3.5 mmol/L)
- Severe: Total calcium >14 mg/dL (>3.5 mmol/L)
Severe hypercalcemia or rapidly rising calcium causes nausea, vomiting, dehydration, confusion, somnolence, and coma, while mild hypercalcemia may only cause fatigue and constipation in 20% of patients 1.
Step 2: Measure Intact PTH (Most Critical Test)
This single test divides the differential into two distinct pathways 1, 3:
PTH Elevated or Normal → PTH-Dependent Hypercalcemia
- Primary hyperparathyroidism (PHPT) - most common cause
- Familial hypocalciuric hypercalcemia (FHH)
- Tertiary hyperparathyroidism
- Lithium-induced hypercalcemia
- Parathyroid carcinoma (rare)
PTH Suppressed (<20 pg/mL) → PTH-Independent Hypercalcemia
- Malignancy - second most common cause overall
- Vitamin D intoxication
- Granulomatous diseases (sarcoidosis, tuberculosis)
- Hyperthyroidism
- Immobilization
- Medications (thiazides, calcium/vitamin D supplements)
Note: Approximately 90% of hypercalcemia cases are due to either PHPT or malignancy 1.
Step 3: PTH-Dependent Pathway (Elevated/Normal PTH)
For Primary Hyperparathyroidism:
- Measure 24-hour urine calcium to exclude FHH (calcium/creatinine clearance ratio <0.01 suggests FHH)
- Check vitamin D (25-OH) levels
- Obtain renal function (creatinine, eGFR)
- Assess bone density (DEXA scan) if considering observation
- Renal imaging (ultrasound or CT) to evaluate for nephrolithiasis or nephrocalcinosis
For Suspected Parathyroid Carcinoma:
- Markedly elevated PTH (often >5x upper limit)
- Palpable neck mass
- Severe hypercalcemia (>14 mg/dL)
- Consider neck imaging and surgical referral
Step 4: PTH-Independent Pathway (Suppressed PTH)
Malignancy Workup:
- PTH-related peptide (PTHrP) - elevated in humoral hypercalcemia of malignancy
- 1,25-dihydroxyvitamin D - elevated in lymphomas and granulomatous disease
- Serum protein electrophoresis/immunofixation - for multiple myeloma
- Age-appropriate cancer screening if no known malignancy
- CT chest/abdomen/pelvis if malignancy suspected
Other Causes:
- 25-OH vitamin D levels - for vitamin D intoxication
- Thyroid function tests - TSH, free T4
- Medication review - thiazides, lithium, calcium/vitamin D supplements, vitamin A
- ACE level and chest imaging - if sarcoidosis suspected
Step 5: Clinical Context Considerations
Medication-Induced:
- Discontinue suspected medications (thiazides, lithium, calcium, vitamin D, vitamin A)
- Recheck calcium in 2-4 weeks after discontinuation
Immobilization:
- Common in bedridden patients, especially with high bone turnover
- Consider mobilization strategies
Emerging Causes (<1% of cases) 1:
- SGLT2 inhibitors
- Immune checkpoint inhibitors
- Denosumab discontinuation (rebound hypercalcemia)
- Post-COVID-19
- Ketogenic diets
- Extreme exercise
Common Pitfalls to Avoid
- Don't assume PHPT without measuring PTH - malignancy can present similarly
- Don't forget to correct calcium for albumin - or measure ionized calcium directly
- Don't overlook medication history - thiazides and supplements are common culprits
- Don't miss FHH - measuring urine calcium prevents unnecessary parathyroid surgery
- Don't delay treatment in severe hypercalcemia - this is a medical emergency requiring immediate hydration and antiresorptive therapy
When to Refer
- Endocrinology: Confirmed PHPT requiring surgical evaluation, parathyroid carcinoma, complex cases
- Oncology: Suspected or confirmed malignancy-associated hypercalcemia
- Surgery: PHPT meeting criteria for parathyroidectomy (age <50, calcium >1 mg/dL above normal, kidney stones, reduced bone density, eGFR <60)
- Nephrology: Severe hypercalcemia with renal failure requiring dialysis
This algorithmic approach, driven by PTH measurement, efficiently narrows the differential diagnosis and guides targeted additional testing based on the specific pathway identified 1, 3.